The Leading Formulation Platform for Medical Cannabis: Precision, Stability & Controlled Release

Transform cannabinoids into advanced dosage forms — granules, pellets, oils, modified‑release systems, and more.

Key value points:

GMP‑grade formulation engineering
Controlled‑release cannabinoid technologies
Stability‑optimized systems for THC, CBD, and minor cannabinoids
Scalable development for clinical and commercial use

Request a Technical Brief

Explore the platform

technology overview

Our Formulation Platform for Medical Cannabis

Cannabinoid stability management: Cannabinoids degrade under heat, oxygen, and light. We support granulation and encapsulation platforms that prevent potency loss and ensures shelf‑life integrity.
Bioavailability optimization: re-emulsifying drug delivery systems (REDDS) technologies, granulation or protective layering can improve absorption or oral bioavailability.
Precision in controlled drug release: modified release is a key value of our platforms serving the right drug dose at the right time:
- Immediate‑release
- Extended‑release
- Sustained‑release
- Multi‑phase release profiles
What is the desired dose your patients like to see? Our medical cannabis platforms are compatible with multiple dosage forms:
- Granules
- Pellets
- Oils
- Capsules

formulation platform for medical cannabis – modified release

Dosage Forms & Applications

Advanced Dosage Forms for Medical Cannabis

Advanced dosage forms transform cannabinoids from raw extracts into predictable, patient‑centric medicines. They represent the next step in medical cannabis innovation — bridging botanical complexity with pharmaceutical precision.

Precision‑Engineered Delivery Systems

Our formulation platform for medical cannabis enables the creation of dosage forms that combine pharmaceutical precision with cannabinoid functionality. Each system is designed to optimize bioavailability, stability, and patient compliance, ensuring consistent therapeutic outcomes.

Core‑Shell Pellets

Core‑shell pellets on our formulation platform for medical cannabis enable precise, controlled cannabinoid release under GMP regulatory.

Controlled release architecture: Layered starter spheres regulate cannabinoid release over time.
Uniform particle size: Allow reproducible drug dosing and predictable pharmacokinetics.
Scalable manufacturing: Compatible with fluid‑bed layering technologies.
Applications: Ideal for modified‑release oral capsules, combination therapies, and flexible dosing.

Granules

Granules developed on our formulation platform for medical cannabis deliver stable, customizable cannabinoid release for oral dosage forms.

Versatile formulation base: Granules serve as intermediates for tablets, sachets, or suspension systems.
Enhanced stability: Protects cannabinoids from oxidation and light degradation, and improves water-solubility.
Custom release profiles: Immediate, delayed, or sustained release options achievable.
Patient‑friendly: Enables flexible dosing, user-friendly, taste‑masked formulations.

Oils

Our oil-based NRF system for medical cannabis maximize cannabinoid bioavailability and ensure consistent therapeutic outcomes.

Flexible dronabinol dosing: from 5 to 25 mg/ml
standardized manufacturing specifications (NRF): for the synthetic cannabinoid dronabinol (delta-9-THC), prepared in pharmacies as a compounded formulation.

Modified‑Release Technologies

Modified‑release technologies on our formulation platform for medical cannabis deliver precise, long‑acting cannabinoid release.

Matrix systems: Control drug release and minimizing dose dumping risks.
Layered multiparticulates: Enable controlled release for complex therapeutic needs.
Smart excipient selection: Balances solubility, permeability, and stability for each cannabinoid.

Integration with Analytical & Regulatory Standards

Every pharmaceutical dosage form developed on our formulation platform for medical cannabis aligns with GMP guidelines, ensuring reproducibility, compliance and trust with evolving medical cannabis regulations.

formulation platform for medical cannabis – pellets granules extended releaase GMP CBD THC dronabinol

Why a Formulation Platform Matters

Why Pharmaceutical‑Grade Formulation Is Essential in Medical Cannabis

Pharmaceutical‑grade formulation is not just a technical requirement — it’s the foundation for safe, standardized, and clinically reliable medical cannabis therapies. It ensures that every dose delivers what science promises: precision, stability, and efficacy.

Our formulation platform for medical cannabis standardizes every batch, ensuring consistent therapeutic outcomes and reproducible pharmacokinetics — essential for clinical reliability and patient trust.

Cannabinoids are bitter, hydrophobic, and unstable, requiring engineered delivery systems.
Without proper formulation, products suffer from oxidation and degradation, potency loss, or inconsistent dosing.
Patients need reliable dosage forms, minimized side effects, and steady therapeutic levels.

Platform Features

Key Features of Our Formulation Platform for Medical Cannabis

Customizable cannabinoid profiles (THC, CBD; minor cannabinoids on demand)
Controlled‑release engineering
Scalable manufacturing compatibility
Regulatory‑aligned workflows
Patient-centric dosage forms

Medical Platforms for Your Needs

Platform	ING-016	ING-015	ING-020	ING-025	ING-010
complies	food / (pharma)	pharma	pharma	pharma	pharma
Ready-to-use	✓
CBD	✓	✓	–	–	✓
THC / dronabinol	–	(✓)	✓	✓	✓
Dosage form	granule	granule / tablet	granule / tablet	oil	layered pellet
Release profile	IR	IR	IR	IR	ER
Information	nanoemulsion, HACCP, mild taste, <8% CBD	SAM, >50% drug load, 100-200 mg/dose	nabilone ASD prototypes	dronabinol-NRF; Sesamöl, no miglyol	MR pellets, API combination
Availability	on market: 2% to 6% CBD	customized	customized	customized	customized

food/nutra

ING-016, CBD Powder

<8% CBD, 0.0% THC
granules
immediate release
shelf-life 2 years
REDDS – re-emulsifying drug delivery system; as micro- or nanoemulsion
instant solution for food (ready to use), HACCP quality/compliant
mild taste
good powder flow for processing
Also available in pharma grade (ING-016)

Extended release pellets

ING-010

CBD
coated pellet (prototype)
extended release
different targeted profiles possible
status: feasibility studies

Granule in capsules

ING-015

30% CBD, semi-synthetic API
granules
immediate release
shelf-life 18 months, ICH stability confirmed
SAM – self-assembling micelles
can be formulated into a break notch tablet, 100-200 mg dosis
placebo tablets available
bioequivalent à reference NRF CBD oil

THC, film coated tablet

ING-020

2,5-5-10 mg dosis THC/dronabinol
granules/tablets
immediate release
SAM
status: placebo tablets in development

NRF-equivalent THC

ING-025

5-25 mg/mL dronabinol-NRF
in sesame oil
immediate release
bulk production (reference material)

Applications & Case Studies

We provide formulation solutions for:

Cannabinoid stability & degradation pathways
Bioavailability enhancement strategies
Dosage form selection guides
Patient‑friendly and safe drug uptake

Request a technical brief

Project Twenty21 Australia - medical cannabis formulations controlled release-small

Applications & Case Studies

Use Cases & Industries

Pharmaceutical developers
Clinical research organizations
Medical cannabis manufacturers
Novel dosage form innovators
Wellness & therapeutic product companies

Scientific Resources & Insights

Provide articles, whitepapers, and technical briefs:

Cannabinoid stability & degradation pathways
Bioavailability enhancement strategies
Dosage form selection guides
Patient‑friendly formulation explanations (based on ISCPh guidance)

The Leading Formulation Platform for Medical Cannabis: Precision, Stability & Controlled Release

Transform cannabinoids into advanced dosage forms — granules, pellets, oils, modified‑release systems, and more.

Our Formulation Platform for Medical Cannabis

Advanced Dosage Forms for Medical Cannabis

Precision‑Engineered Delivery Systems

Why Pharmaceutical‑Grade Formulation Is Essential in Medical Cannabis

Key Features of Our Formulation Platform for Medical Cannabis

Medical Platforms for Your Needs

ING-016, CBD Powder

ING-010

ING-015

ING-020

ING-025

Applications & Case Studies

Project Twenty21 Australia: Medical Cannabis May Be a Useful Treatment Option

Cannabis Health Symposium 2026

Cannabis Health Symposium in Germany

Safety assessment of medical cannabis end‑products

MedCan Trend Report 2026 – an Overview

CBD Release Profile: Granule vs. Oil

Attending PTMC 2026

Applications & Case Studies

Use Cases & Industries

Scientific Resources & Insights

CONTACT